Abliva Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Abliva
Access all reports
Abliva AB, engages in the research and development of mitochondrial medicine for the treatment of neurodegenerative diseases in Sweden. The company's lead candidate is NGM282, an engineered hormone that drives expression of the human glucokinase gene, which is in Phase 2b/3a clinical study as a once-weekly treatment for type 2 diabetes and has completed Phase 1b/2a clinical study to treat non-alcoholic steatohepatitis; and completed a Phase 2 clinical study in patients with primary biliary cholangitis disease.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ABLI
Country
🇸🇪 Sweden